Geneva, April 20 -- International Clinical Trials Registry received information related to the study (NCT07526597) titled 'Study on Treatment Outcome Patterns for Patients With CLL After Discontinuation of BTK Inhibitors' on April 6.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: UNC Lineberger Comprehensive Cancer Center

Condition: Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma

Intervention: Other: Discontinuing Bruton tyrosine kinase inhibitors (BTKi) therapy

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: May 2026

Target Sample Size: 45

Countries of Recrui...